Wedbush Securities Inc Beam Therapeutics Inc. Transaction History

Wedbush Securities Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 21, 2022	SELL	$29.86 - $62.36 $117,200 - $244,763	-3,925 Closed	0 $0
Q1 2022 Apr 19, 2022	SELL	$53.73 - $82.16 $8,059 - $12,324	-150 Reduced 3.68%	3,925 $224,000
Q4 2021 Jan 13, 2022	BUY	$68.02 - $99.06 $1,020 - $1,485	15 Added 0.37%	4,075 $324,000
Q3 2021 Oct 08, 2021	BUY	$84.37 - $133.6 $2,952 - $4,676	35 Added 0.87%	4,060 $353,000
Q2 2021 Jul 27, 2021	BUY	$64.12 - $128.71 $8,015 - $16,088	125 Added 3.21%	4,025 $518,000
Q1 2021 Apr 26, 2021	BUY	$71.28 - $120.75 $24,948 - $42,262	350 Added 9.86%	3,900 $312,000
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $78,952 - $339,486	3,550 New	3,550 $290,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.